Atezolizumab, an anti-PD-L1 antibody, has also been evaluated in combination with chemotherapy in the phase 1 GP28328 study (NCT01633970) in multiple tumor types, demonstrating improved ORR of CIT in patients with NSCLC (41). Here, CD274 is linked to neoplasm.